Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
… X: Late-breaking clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be … PhD, Sr. scientist computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: … Western world have LCA10 because of this mutation. About Axiomer ® Technology Platform ProQR is pioneering a …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… EST This presentation will highlight ProQR’s proprietary Axiomer ® platform, a fully owned and in house developed RNA … in the retina with oligonucleotide therapeutics. About Axiomer ® platform technology ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …